Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
How would you approach a young, fit patient with suspected CNS involvement with high circulating blasts?
What induction and IT regimens do you use for patients with confirmed AML with CNS involvement?
Related Questions
In patients with post-PV myelofibrosis who are ineligible for allogeneic stem cell transplant, how do you approach symptomatic splenomegaly refractory to splenic radiation and ruxolitinib?
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
How do you approach neutropenia in patients being treated with obinutuzumab/venetoclax for CLL?
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
For patients with newly diagnosed AML who are induction chemotherapy eligible, do you dose reduce cytarabine for any mild elevation in AST/ALT?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
Do you add venetoclax +/- anti CD-20 mAb to a BTKi in patients with CLL who no longer wish to remain on a BTKi many months after starting the BTKi?
Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?
What are your top takeaways in Hematologic Malignancies from ASH 2024?